Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.55 |
| ▸ | IGF1R | P08069 | 10/20 | 0.47 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.41 |
| ▸ | ULK1 | O75385 | 4/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | PAK4 | O96013 | 1/20 | 0.37 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13054561 | 0.96 | NTRK1 (0.53) | NTRK1IGF1RHSF1PIK3C3ULK1 | |
| SCHEMBL3769748 | 0.85 | HSF1 (0.41) | NTRK1IGF1RHSF1BRD4 | |
| SCHEMBL13055840 | 0.84 | IGF1R (0.42) | NTRK1IGF1RPIK3C3ULK1PDK1 | |
| SCHEMBL3766793 | 0.83 | HSF1 (0.43) | NTRK1IGF1RHSF1BRD4 | |
| SCHEMBL13054541 | 0.83 | PAK4 (0.47) | IGF1RULK1PAK4PAK1 | |
| SCHEMBL13054536 | 0.81 | ULK1 (0.48) | NTRK1IGF1RULK1PDK1ULK2 | |
| SCHEMBL13081761 | 0.81 | ULK1 (0.40) | IGF1RULK1PDK1ULK2PAK4 | |
| SCHEMBL13054498 | 0.80 | SRC (0.46) | IGF1RULK1PDK1ULK2PAK4 | |
| SCHEMBL13081885 | 0.79 | PAK4 (0.42) | IGF1RULK1PDK1ULK2PAK4 | |
| SCHEMBL3768412 | 0.77 | HSF1 (0.46) | HSF1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842712-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| US-7262200-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262200-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | LCK, CDK2, MKNK2 | NTRK1 1279/4885IGF1R 687/4885HSF1 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.